Hello, Welcome to Shine Consultant !
Summit & Event Shine Speaker Bureau Shine Advisor Shine Event Service
  • Summit & Event :
    With field research of markets and industries which is analyzed from a global strategic perspective by our professional teams, as well as hot topics which interest leadership and management, Shine Consultant provides you with one-stop platform of dialogue, practice -sharing and social network!
  • Shine Speaker Bureau:
    Committed to provide keynote speakers, executive learning masterclasses and boardroom advisory for global enterprises and institutions, each service provides a deeper and more interactive experience, especially for small, selected audiences and key individuals. We have the resources of the most influential business leaders and experts, who are the most outstanding representatives in their fields. Our team consists of experienced speech and event managers, and we focus on building long-term and in-depth partnerships.
  • Shine Advisor:
    As world-class insight network, we connects clients-decision makers with vetted subject matter experts-advisors. Our clients leverage the insights and perspectives shared by our advisors to stay informed and make better business decisions.We have over 600,000 Shine Advisors in 20 industries, which continues to grow every day.
  • Shine Event Service:
    Committed to be the world's most professional provider of industrial Summit & Event. We provide one-stop professional services, including investigating and planning, on-demand inviting, marketing and promoting, operating, project management, live& digital conference, each service is performed by an experienced professional team matched with long-term industrial resources. We focus on establishing long-term and in-depth partnerships.
Guest Information
Dr. Tse Wen Chang
Dr. Tse Wen Chang
Positions:

 founder and CEO

Company:

  Immunwork, Inc

Dr. Chang cofounded Tanox in Houston, Texas in 1986 and invented in 1987 the anti-IgE therapy, leading to the development of talizumab, omalizumab (Xolair), and ligelizumab. Xolair has been approved for treating severe allergic asthma and severe chronic spontaneous urticaria. He returned to Taiwan in 1996 to serve as the dean of the College of Life Sciences, Tsing Hua University, and subsequently the President of Development Center for Biotechnology. He was a Distinguished Research Fellow in the Genomics Research Center in Academia Sinica in 2006-2015. His group discovered CemX domain on membrane IgE and developed an anti-CemX antibody UB221, which is in clinical development. Dr. Chang is now leading Immunwork to develop “T-E technology” platform, which can be used to create new drugs with both targeting and effector moieties. More than 20 new drugs have been designed for applications in oncology, autoimmune, infectious, CNS diseases, and other disease